News

Filter

Current filters:

Rare diseases

1 to 9 of 562 results

Shire acquires Meritage Pharma, strengthening rare diseases pipeline

Shire acquires Meritage Pharma, strengthening rare diseases pipeline

24-02-2015

In a second acquisition this year, Ireland-headquartered Shire revealed today that it has taken control…

BiotechnologyGastro-intestinalsMergers & AcquisitionsMeritage PharmaRare diseasesShire

Marathon Pharma sells non-strategic products to Valeant

24-02-2015

Marathon Pharmaceuticals, a privately held US biopharmaceuticals company focused on drugs for people…

Marathon PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesValeant Pharmaceuticals International

Sosei acquires Heptares Therapeutics for up to $400 million

Sosei acquires Heptares Therapeutics for up to $400 million

23-02-2015

Japanese drugmaker Sosei Group says it has acquired Heptares Therapeutics, a clinical-stage private UK-based…

BiotechnologyHeptares TherapeuticsMergers & AcquisitionsNeurologicalRare diseasesSosei

EMA Orphan Drug status for aTyr’s Resolaris in FSHD

18-02-2015

Privately-held US biotech firm aTyr Pharma says that the European Commission has granted Orphan Drug…

ATyr PharmaBiotechnologyEuropeRare diseasesRegulationResolaris

Australia to subsidize Genzyme’s Pompe disease drug Myozyme for young patients

Australia to subsidize Genzyme’s Pompe disease drug Myozyme for young patients

17-02-2015

Australia’s Minister for Health Sussan Ley said today that she has approved a life-saving drug that…

AustraliaBiotechnologyFinancialGenzymeHealthcareMyozymeRare diseasesSanofi

UPDATE: FDA approves Eisai’s Lenvima for a type of thyroid cancer and expands use of Banzel

UPDATE: FDA approves Eisai’s Lenvima for a type of thyroid cancer and expands use of Banzel

14-02-2015

The US Food and Drug Administration on Friday granted approval for Japanese pharma major Eisai’s Lenvima…

BanzelEisailenvatinibLenvimaNeurologicalOncologyPharmaceuticalRare diseasesRegulationUSA

Positive Ph III clinical trial extension results for Genzyme’s Cerdelga

Positive Ph III clinical trial extension results for Genzyme’s Cerdelga

13-02-2015

French pharma major Sanofi subsidiary Genzyme has reported positive extension study data from its Phase…

BiotechnologyCerdelgaGenzymeRare diseasesResearchSanofi

Strong 2014 financials from Shire, bolstered by

Strong 2014 financials from Shire, bolstered by "break fee"

12-02-2015

Shares of Ireland-headquartered Shire gained 4.6% to £49.97, after the drugmaker reported pretax profit…

BiotechnologyFinancialRare diseasesShire

1 to 9 of 562 results

COMPANY SPOTLIGHT

Menarini

Back to top